Textron, Inc. (TXT) Misses Q3 EPS by 4c; Boosts FY12 EPS Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts TXT Hot Sheet
Price: $76.83 -1.55%
EPS Growth %: -7.7%
Financial Fact:
Discontinued operations: 0.45
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
EPS Growth %: -7.7%
Financial Fact:
Discontinued operations: 0.45
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Textron, Inc. (NYSE: TXT) reported Q3 EPS of $0.48, $0.04 worse than the analyst estimate of $0.52. Revenue for the quarter came in at $3 million versus the consensus estimate of $3.06 million.
Textron, Inc. sees FY2012 EPS of $1.95-2.05, versus prior guidance of $1.80-2.00 and the consensus of $2.11.
For earnings history and earnings-related data on Textron, Inc. (TXT) click here.
Textron, Inc. sees FY2012 EPS of $1.95-2.05, versus prior guidance of $1.80-2.00 and the consensus of $2.11.
For earnings history and earnings-related data on Textron, Inc. (TXT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- Pfizer's 25-valent pneumococcal vaccine shows Phase 2 results
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
